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Thrombolysis in very elderly people: controlled comparison
of SITS International Stroke Thrombolysis Registry and
Virtual International Stroke Trials Archive
Nishant KMishra, doctoral candidate,1 Niaz Ahmed, neurologist,2 Grethe Andersen, neurologist,3 Jose´ A Egido,
neurologist,4 Perttu J Lindsberg, professor of applied neurology,5 Peter A Ringleb, neurologist,6 Nils G
Wahlgren, professor of neurology,2 Kennedy R Lees, professor of cerebrovascular medicine1 for the VISTA
and SITS collaborators
ABSTRACT
Objective To assess effect of age on response to alteplase
in acute ischaemic stroke.
Design Adjusted controlled comparison of outcomes
between non-randomised patients who did or did not
undergo thrombolysis. Analysis used Cochran-Mantel-
Haenszel test and proportional odds logistic regression
analysis.
Setting Collaboration between International Stroke
Thrombolysis Registry (SITS-ISTR) and Virtual
International Stroke Trials Archive (VISTA).
Participants 23334 patients from SITS-ISTR (December
2002 to November 2009) who underwent thrombolysis
and 6166 from VISTA neuroprotection trials (1998-2007)
who did not undergo thrombolysis (as controls). Of the
29500 patients (3472 aged >80 (“elderly,” mean 84.6),
data on 272 patients were missing for baseline National
Institutes of Health stroke severity score, leaving 29228
patients for analysis adjusted for age and baseline
severity.
Main outcomemeasures Functional outcomes at 90 days
measured by score on modified Rankin scale.
ResultsMedian severity at baseline was the same for
patients who underwent thrombolysis and controls
(median baseline stroke scale score: 12 for each group,
P=0.14; n=29228). The distribution of scores on the
modified Rankin scale was better among all thrombolysis
patients than controls (odds ratio 1.6, 95% confidence
interval 1.5 to 1.7; Cochran-Mantel-Haenszel P<0.001).
The association occurred independently among patients
aged ≤80 (1.6, 1.5 to 1.7; P<0.001; n=25789) and in
those aged >80 (1.4, 1.3 to 1.6; P<0.001; n=3439). Odds
ratioswere consistent across all 10 year age ranges above
30, and benefit was significant from age 41 to 90;
dichotomised outcomes (score on modified Rankin scale
0-1 v 2-6; 0-2 v 3-6; and 6 (death) v rest) were consistent
with the results of the ordinal analysis.
Conclusions Outcome in patients with acute ischaemic
stroke is significantly better in those who undergo
thrombolysis comparedwith thosewhodo not. Increasing
age is associated with poorer outcome but the
association between thrombolysis treatment and
improved outcome is maintained in very elderly people.
Age alone should not be a barrier to treatment.
INTRODUCTION
Thrombolysis for acute ischaemic stroke has proved
benefits,1-5 but data from randomised trials in patients
aged over 80 are limited. About 30% of acute stroke
occurs in people aged over 80.6-8 The NINDS
(National Institute of Neurological Disorders and
Stroke) trial initially restricted enrolment to patients
aged up to 80.9 The age criterion was lifted after they
enrolled 188 patients in part A of the trial, but they
enrolled only 42 very elderly patients.2 All ECASS
(European Cooperative Acute Stroke Study) trials
applied an upper age limit of 80,3 10 and recent studies
with desmoteplase (a fibrin specific plasminogen
activator)11 12 also excluded elderly patients. Thus, up
to now, the European Medicines Evaluation Agency
has not approved thrombolysis with alteplase among
patients aged above 80.4 Many experienced centres
treat elderly patients but others observe the terms of
product approval.13-16
The main reasons for withholding treatment from
very elderly patients in clinical practice are fears that
advancing age is associatedwith poorer prognosis with
greater risk for haemorrhage and in hospital
mortality.17-19 Conversely, a meta-analysis of pooled
thrombolysis data concluded that the risks of sympto-
matic intracerebral haemorrhage did not increase
among elderly patients, despite less favourable
outcomes.15 20 Less favourable outcomes are expected
to occur in elderly patients, mostly because of
comorbidity.1 9 21
The proportion of older people is rising in our
society,6-8 and the proportion of those undergoing
thrombolysis will decline in the future if patients aged
over 80 are not treated.22 In theUnitedKingdomalone,
1Acute Stroke Unit, University
Department of Medicine and
Therapeutics, Gardiner Institute,
Western Infirmary and Faculty of
Medicine, University of Glasgow,
Glasgow G11 6NT, UK
2Department of Neurology,
Karolinska University Hospital,
Karolinska Institutet 171 76
Stockholm, Sweden
3Department of Neurology,
Aarhus University Hospital,
Aarhus, Denmark
4Department of Neurology,
Hospital San Carlos, Spain
5Department of Neurology,
Helsinki University Central
Hospital, and Program of
Molecular Neurology, University of
Helsinki, Helsinki, Finland
6Department of Neurology,
University Hospital of Heidelberg,
Heidelberg, Germany
Correspondence to: K R Lees
k.r.lees@clinmed.gla.ac.uk
Cite this as: BMJ 2010;341:c6046
doi:10.1136/bmj.c6046
BMJ | ONLINE FIRST | bmj.com page 1 of 9
the population aged over 80 has doubled since 1982,23
and life expectancy has risen in the rest of Europe and
in other countries.24 Effective treatments, however,
should not be withheld from older people in the
absence of compelling data suggesting unacceptable
risk or proved lack of benefit. We hypothesised that
clinical practice over the past decade would have
been sufficiently diverse to allow analysis of existing
rigorously collected clinical data2526 to construct a com-
parison of thrombolysis against matched controls, with
the possibility of adjusting for any imbalance in sever-
ity. We anticipated that use in older people would be
sufficiently common to assess the influence of age on
any association of stroke outcome with thrombolysis.
METHODS
Data source and patients
We collated the data of stroke patients who underwent
thrombolysis through the SITS-ISTR (Safe Implemen-
tation of Treatment in Stroke-International Stroke
Thrombolysis Registry, www.sitsinternational.org,
held at Karolinska University Hospital, Stockholm)
fromDecember 2002 to November 2009. Our control
group comprised untreated stroke patients from neu-
roprotection trials conducted from 1998 to 2007 and
held within the Virtual International Stroke Trials
Archive, VISTA (www.vista.gla.ac.uk).26
The SITS-ISTR is an ongoing internet based, aca-
demic driven, interactive thrombolysis register. The
methods of the register, including the procedure for
data collection and management, identification of
patients, and verification of source data, has been
described previously.27 5 28 In brief, it is a prospective
open multinational observational monitoring registry
for clinical centres using thrombolysis and other inter-
ventions for the treatment of acute ischaemic stroke.
The registry is open to all countries, and collects data
on patientswho receive thrombolytic therapy for acute
ischaemic stroke.5 28
VISTA is a collaborative, not-for-profit, register of
stroke trials.26 The treatments studied in these trials
range from putative neuroprotectants through anti-
coagulants and thrombolytic agents to simple rehabili-
tation measures.26 Unfortunately, the effects of the
neuroprotectants have largely been indistinguishable
from placebo.29 All trials in VISTA hold necessary
review board and regulatory approvals, and all
patients agreed to participation. The archive holds
only anonymised data, and the source trial is not dis-
closed as per VISTA guidelines.26 For this analysis, we
sought data from the archive from a group of trials in
which the investigated drug was a putative neuropro-
tectant that was neither vasoactive nor interfered with
clotting or from placebo groups. Hence, the “controls”
were patients who did not receive alteplase in neuro-
protection trials but received either placebo or a neu-
roprotective drug as per the randomisation protocol
for each contributing trial. From both of these sources,
we collated the demographics, clinical data, and
information of functional outcome as measured by
the score on the modified Rankin scale after 90 days.
Patient sample
We downloaded data on 28 136 patients registered in
SITS-ISTR from 25 December 2002 to 2 November
2009 and extracted information on 23 336 who had
completed 90 day follow-up. Two patients were
excluded because of inexact information on age, leav-
ing 23 334. Participating centres agreed to record
details of every patient treated with intravenous alte-
plase at that centre and to enter baseline data as soon
as possible after treatment, adding outcomes as they
occurred.27
We collated data on 9665 patients from VISTA. Of
these, 6371 patients who had ischaemic stroke and did
not undergo thrombolysis were selected as controls.
We excluded 205 patients with no information on
functional outcomes at 90 days, leaving 6166 for
analysis.
Of the 29 500 patients (n=3472 aged >80), data on
baselineNational Institutes ofHealth stroke scale score
were missing for 272 patients, leaving 29 228 for ana-
lysis adjusted for age and baseline severity (fig 1 ).
Statistical analysis
We compared outcome at 90 days in patients who
received intravenous thrombolysis and controls for
the whole cohort. We repeated the comparison
among patients aged ≤80 and >80 years. We then
examined the association of thrombolysis treatment
with outcome within various age groups (<21, 21-30,
31-40, 41-50, 51-60, 61-70, 71-80, 81-90, and 91-100)
to illustrate the strength of evidence across the full age
range.
For each comparison, we looked at the overall dis-
tribution of all seven categories of scores on the mod-
ified Rankin scale in the two groups at day 90. The
modified Rankin scale is an ordinal score used as a
measure of functional outcomes in patients with stroke
(see box).30 31
Scores on modified Rankin scale
0=no symptoms from stroke
1=no severe disability, despite symptoms
2=slight disability in which patients are unable to do all
previous activities but able to look after themselves
without help
3=moderate disability that requires some help, but
patients can walk by themselves
4=moderately severe disability in which patients are
unable to walk without assistance and need help for
bodily needs
5=bedbound patients who are incontinent or require
personal attention
6=death
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To test for a significant association of distribution of
outcome with exposure to thrombolysis we used the
Cochran-Mantel-Haenszel statistic, adjusting for age
and baseline score on the National Institutes of Health
stroke scale as continuous variables.32 33 We had two
reasons for our choice of baseline factors for adjust-
ment. Firstly, age and baseline severity measured by
National Institutes of Health stroke scale are the two
most powerful prognostic factors for stroke outcome
and are usually included in analyses of outcome
distribution.32-36 Secondly, we had data on age and
the stroke scale for our entire sample, whereas data
on other factors of potential interest were incomplete.
We also undertook a sensitivity analysis by consider-
ing the combined effect of the variables that differed
significantly at baseline.
Our objective was mainly to undertake an ordinal
distribution or “shift” analysis, which is an efficient
endpoint analysis technique accepted by the European
Agency for the Evaluation of Medicinal Products
(EMEA).37 Shift analysis is considered to be better
than dichotomisation of endpoint measures, though
there are differences of opinion.38-43 Dichotomisation
is criticised for the statistical information it discards,
whereas shift analysis is especially useful when the
treatment effect is mild or uniform, or both, across all
Rankin categories, though in larger datasets it can
sometimes incorrectly seem to violate proportionality
assumptions.38-40 44 This is because the test for propor-
tionality assumptions is described as “sensitive to sam-
ple size, such that large samples may produce
statistically significant P values when in fact there is
little practical difference between the cut-point-specific
estimates.”45 Hence, though we planned to undertake
examination of outcomes by proportional odds logistic
regression analysis we also elected to undertake sec-
ondary analyses, dichotomising the Rankin scores 0-1
v rest, 0-2 v rest, and dead v survivors, to allow
comparability of our findings with the other published
data.46Odds ratios in our analysis express the common
odds of an improved distribution of outcome in asso-
ciation with treatment with alteplase.
The Cochran-Mantel-Haenszel test and propor-
tional odds logistic regression analysis were underta-
ken with SAS 9.2 software and other analyses by
StatsDirect software. We describe our findings in
accordance with the STROBE guidelines.47
Reliable information on symptomatic intracerebral
haemorrhage was not available from VISTA controls
as post-treatment imaging was not routinely carried
out in neuroprotection trials in patients who had not
been treated with alteplase. However, we compared
the rates of symptomatic intracerebral haemorrhage
for the definitions used within SITS (local or remote
parenchymal haemorrhage type 2 on the imaging
scan 22-36 hours after treatment, combinedwith a neu-
rological deterioration of 4 or more points on the
National Institutes of Health stroke severity scale
from baseline, or from the lowest National Institutes
of Health stroke severity score between baseline and
24 hours, or leading to death) and the NINDS study
(any intracranial haemorrhage in the post-thromboly-
sis imaging scans if it was not seen on a previous ima-
ging scan and any decline in neurological status) for
younger and older patients of the SITS-ISTR registry.
RESULTS
All stroke patients were treated as per institutional
practice and stroke guidelines acceptable at the point
of their treatment. The table shows the baseline char-
acteristics. Baseline severity of stroke was similar
between patients who did and did not undergo throm-
bolysis among those aged>80 (P=0.6) and ≤80 (P=0.3).
Independently, baseline National Institutes of
Health stroke scale accounted for 25.5% and age for
7.4% of the variation in 90 day outcome by modified
Rankin scale (both P<0.001) and were included in all
models, together explaining 29.6% of the variation.
Overall outcome
Across our whole sample, the distribution of scores on
themodifiedRankin scale at threemonthswas better—
that is, more patients had lower scores—among those
who underwent thrombolysis (fig 2). The overall odds
ratio was 1.6 (95% confidence interval 1.5 to 1.7;
P<0.001) (fig 3).
Outcomes among patients aged ≤80
Treatmentwith thrombolysis was associatedwith a sig-
nificantlymore favourable distribution of scores on the
modified Rankin scale at three months (fig 2). The
adjusted odds ratio was 1.6 (1.5 to 1.7); P<0.001; n=
25 789 (fig 3). P for test of proportionality assumption
was <0.05. The unadjusted odds ratio was 1.5 (1.4 to
1.6) (n=26 028). Dichotomised outcomeswere also sig-
nificantly more favourable for thrombolysed patients
than controls (1.9 (1.7 to 2.0) for score 0-2 v 3-6 on
VISTA database (n=9665)SITS-ISTR Dec 2002-Nov 2009 (n=28 136)
SITS-VISTA study cohort (n=29 500)
Data on baseline stroke scale score missing for 272, leaving 29 228 patients for adjusted analyses
Excluded 607 patients with
non-ischaemic stroke (n=9058)
Excluded 3727 patients because of missing data
on functional outcome at 90 days (n=24 409)
Excluded 2687 patients who received recombinant
tissue type plasminogen activator (n=6371)
Excluded 1073 patients who did not reach
3 month follow-up by 2 Nov 2009 (n=23 336)
Excluded 205 patients because of missing data
on functional outcome at 90 days (n=6166)
Excluded 2 patients with incorrect age
(n=23 334)
Total non-thrombolysed patients from VISTA
included in this study (n=6166)
Total thrombolysed patients from SITS-ISTR
included in this study (n=23 334)
Fig 1 | Description of analysed patients from two data sources
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modifiedRankin scale; 1.6 (1.4 to 1.7) for excellent out-
come (score 0-1 v 2-6), and 0.87 (0.79 to 0.95) for mor-
tality).
Our sensitivity analysis, in which we adjusted for
age, sex, history of either diabetes or previous stroke,
previous use of antithrombotics, baseline National
Institutes of Health stroke severity score, and hyper-
tension, yielded Cochran-Mantel-Haenszel P<0.001
and proportional odds of 1.6 (1.4 to 1.7) in favour of
thrombolysis.
The results indicate that 8.5 patients aged ≤80 need
to be treated for onemore patient to achieve amodified
Rankin scale score of 0-2.
Outcomes among patients aged >80
Among the 3439 patients aged over 80 with a 90 day
score on the modified Rankin scale and baseline data
on stroke severity, treatment with thrombolysis was
associated with a significantly more favourable distri-
bution of scores at three months compared with con-
trols (fig 2). The adjusted odds ratiowas 1.4 (1.3 to 1.6);
P<0.001; n=3439 (fig 3. P for test of proportionality
assumption was <0.05. The unadjusted odds ratio
was 1.4 (1.2 to 1.6), ( P<0.001; n=3472). Dichotomised
outcomes were significantly more favourable for
thrombolysed patients than controls (2.1 (1.7 to 2.5)
for favourable outcome (score 0-2 onmodified Rankin
scale); 1.9 (1.5 to 2.3) for excellent outcome (score 0-1);
and 0.89 (0.76 to1.04) for mortality).
Our sensitivity analysis, in which we adjusted for
age, sex, history of either diabetes or previous stroke,
previous use of antithrombotics, baseline National
Institutes of Health stroke severity score, and hyper-
tension, yielded Cochran-Mantel-Haenszel P=0.003
and proportional odds of 1.5 (1.3 to 1.8) in favour of
thrombolysis.
The results indicate that 8.2 patients aged >80 need
to be treated for onemore patient to achieve amodified
Rankin scale score of 0-2.
Association of thrombolysis with outcome by age groups
Distributions of scores on themodified Rankin scale at
90 days were significantly better among thrombolysed
patients than controls within each 10 year age group
from 40 to 90 and, except among the small samples
of patients younger than 30 and older than 90, point
estimates for the adjusted odds ratios were consistent
across all age groups (fig 3).
Baseline characteristics of patients in SITS*-VISTA
Thrombolysis Control P value
Mean (SD) and median (range) age (years)
All 67.1 (12.4), 69 (10-98); n=23 334 70.1 (12.2), 72 (21-101); n=6166 <0.001
≤80 65.3 (11.63), 68 (10-80); n=21 099 66.5 (10.7), 69 (21-80); n=4929 <0.001
>80 84.4 (3.25), 84 (81-98); n=2235 84.84 (3.36), 84 (81-101); n=1237 <0.001
No (%) of men
All 13 594/23 334 (58.3) 3271/6166 (53.0) <0.001
≤80 12 744/21 099 (60.4) 2783/4929 (56.5) <0.001
>80 850/2235 (38.0 488/1237 (39.5) 0.41
Median (range) baseline score on National Institutes of Health stroke scale
All 12 (0-42), n=23 062 12 (2-37), n=6166 0.14
≤80 12 (0-42), n=20 860 11 (2-32), n=4929 0.32
>80 14 (0-39), n=2202 14 (2-37), n=1237 0.61
No (%) who had previously taken antithrombotics
All 8776/22 792 (38.5) 1267/2968 (42.7) <0.001
≤80 7537/20 623 (36.5) 977/2414 (40.5) <0.001
>80 1239/2169 (57.1% 290/554 (52.3) 0.04
No (%) with known diabetes mellitus
All 3962/22 968 (17.2) 1449/5896 (24.6) <0.001
≤80 3570/20 784 (17.2) 1203/4704 (25.6) <0.001
>80 392/2184 (17.9) 246/1192 (20.6) 0.06
No (%) with previous stroke
All 3005/23 013 (13.1) 2014/5993 (33.6) <0.001
≤80 2629/20 840 (12.6) 1521/4776 (31.8) <0.001
>80 376/2173 (17.3) 493/1217 (40.5) <0.001
No (%) with congestive heart failure
All 1932/22 840 (8.5) 277/3167 (8.7) 0.59
≤80 1581/20 697 (7.6) 185/2579 (7.2) 0.39
>80 351/2143 (16.4) 92/588 (15.6) 0.67
No (%) with hypertension
All 14331/22 875 (62.6) 4170/5896 (70.7) <0.001
≤80 12687/20 683 (61.3) 3273/4704 (69.6) <0.001
>80 1644/2192 (75) 897/1192 (75.3) 0.87
No (%) with atrial fibrillation
All 5835/22 753 (25.6) 1712/5896 (29.0) <0.001
≤80 4837/20 613 (23.5) 1147/4704 (24.4) 0.19
>80 998/2140 (46.6) 565/1192 (47.4) 0.67
*Of patients with baseline National Institutes of Health stroke scale score in SITS datasheet, two (0.32%) in age
group 31-40, five (0.30%) in age group 41-50, nine (0.25%) in age group 51-60, six patients (0.1%) in age
group 61-70, eight (0.09%) in age group 71-80, and two (0.1%) in age group 81-90 were coded as having
baseline score of 0 and treated with alteplase. They were assumed to have neurological deficit considered
potentially disabling but not measured by restricted rules of the scale (such as distal limb weakness). These
few cases will have no material impact on findings.
Death5Modified Rankin score 4320
18.7
Alteplase
(n=23 334)
Control
(n=6166)
All patients
19.3 15.8 13.0 5.612.3 15.4
10.8 16.9 11.9 13.9 19.3 8.3 18.9
1
19.6
Alteplase
(n=21 099)
Control
(n=4929)
Age ≤80
20.0 16.4 13.2 5.012.2 13.6
12.1 19.1 13.2 14.5 19.3 7.1 14.8
9.5
Alteplase
(n=2235)
Control
(n=1237)
Age >80
12.8 10.6 11.0 10.712.9 32.6
5.7 8.0 7.0 11.3 19.5 13.2 35.3
Fig 2 | Scores on modified Rankin scale (from 0=no symptoms
from stroke to 6=death) at three months between patients
who underwent thrombolysis with alteplase and controls,
indicating shift towards improved outcomes with
thrombolysis. Numbers within coloured cells are percentages
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Functional outcome measured by modified Rankin
scale 0-1 (fig 4), scale 0-2 (fig 5), and survivor (fig 6)
analysis showed similar results in favour of thromboly-
sis. We found no significant interaction of age levels
with the effect of alteplase use on outcome in the entire
dataset (P=0.45 for score 0-2 v rest), those aged >80
(P=0.76 and 0.85 for score 0-2 v rest and 0-1 v rest,
respectively), or those aged ≤80 (0.42 and 0.48 for
score 0-2 v rest and 0-1 v rest, respectively).
Post-thrombolysis intracerebral haemorrhage
The rate of symptomatic intracerebral haemorrhage
per SITS-MOST definition27 (≥4 point increase in
National Institutes ofHealth stroke scale frombaseline
or deathwithin 24 hours andparenchymatous haemor-
rhage (type PH2 or PHr2) at 22-36 hour imaging scans)
was 2.5% (54/2163) among those aged >80 compared
with 1.9% (398/20 759) among those aged ≤80, and
thus not significantly higher (odds ratio 1.3, 0.96 to
1.8; P=0.07). The corresponding rate for symptomatic
intracerebral haemorrhage per National Institute of
Neurological Disorders and Stroke definition27 (any
increase in National Institutes of Health stroke scale
from baseline and any parenchymal intracerebral hae-
morrhage) was significantly higher: 11.0% (229/2087)
v 8.3% (1670/20 220); 1.4, 1.2 to1.6; P<0.001).
Onset to treatment time
We calculated the time from onset of stroke to treat-
ment for the administration of thrombolysis to patients
in SITS-ISTR.Themedian timewas similar in younger
(≤80) and older (>80) patients (145minutes, P=0.25 for
difference). Data on onset to treatment time for use of
alteplase were not collected in VISTA.
DISCUSSION
Principal findings
Comparing patients from SITS who were treated with
alteplase at an average of 145minutes after strokeonset
against controls from VISTA who received no alte-
plase we found more favourable outcomes with alte-
plase across the entire range of scores on the
modified Rankin scale (odds ratio 1.6, 95% confidence
interval 1.5 to1.7, P<0.001). The nature and extent of
this effect of alteplase is comparable with results from
pooled analysis of randomised controlled trials, con-
firming the validity of our controlled but non-rando-
mised analysis.4 We were able to examine outcomes
separately among patients aged ≤80 and older patients
aged>80. In each subgroupwe foundmore favourable
functional outcomes: odds ratios 1.6 (1.5 to 1.7), n=
25 789, and 1.4 (1.3 to 1.6), n=3439, respectively.
Extending our analysis to smaller subgroups of age,
we found independently significant benefits from alte-
plase in each 10 year age group from 40-90. We found
no interaction between age and efficacy of alteplase
and across the full age range from age under 20 to
over 100. Only in patients aged under 30 did the
trend not favour outcomes after use of alteplase.
In summary, we show that association between
thrombolysis treatment and outcome is maintained in
all patients, even in older patients, regardless of gener-
ally poorer outcomes in these age groups.
Strengths and limitations
Our analysis of SITS-VISTA data is based on almost
30000 patients and confirms that there are improved
outcomes after acute ischaemic stroke among patients
who are offered thrombolytic therapy. The extent of the
21-30
31-40
41-50
51-60
61-70
71-80
81-90
91-100
≤80
>80
All age groups
0.86 (0.29 to 2.6)
1.5 (1.0 to 2.1)
1.5 (1.2 to 1.8)
1.6 (1.4 to 1.8)
1.5 (1.4 to 1.7)
1.6 (1.5 to 1.8)
1.5 (1.3 to 1.7)
1.2 (0.69 to 2.0)
1.6 (1.5 to 1.7)
1.4 (1.3 to 1.6)
1.6 (1.5 to 1.7)
170
632
1642
3658
6193
8527
2069
133
20 860
2202
23 062
0.2 0.5 1 2 5
Age group
Favours
control
Favours
alteplase
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Treated
12
104
358
830
1422
2203
1158
77
4929
1237
6166
Control
0.88
0.30
<0.001
<0.001
<0.001
<0.001
<0.001
0.73
<0.001
<0.001
<0.001
Cochran-Mantel-
Haenszel P value
Fig 3 | Shift towards better outcomes on modified Rankin scale at three months adjusted for
age and baseline severity (defined by National Institutes of Health stroke scale). Number of
patients shown for age groups do not add up to 29228 because numbers of patients ages <21
(n=38) and >100 (n=2) were too low to allow any comparison. All patients aged <21 were from
SITS and underwent thrombolysis; 15 patients reached a 90 day modified Rankin score of 0,
10 patients attained a score of 1, eight patients reached a score of 2, one patient achieved a
score of 3, and two a score of 4; two died. Two patients aged 101 did not undergo
thrombolysis in VISTA neuroprotection trials; they achieved modified Rankin score of 0 and 4
at 90 days
21-30
31-40
41-50
51-60
61-70
71-80
81-90
91-100
≤80
>80
All age groups
1.3 (0.36 to 4.6)
1.3 (0.83 to 2.1)
1.3 (1.0 to 1.7)
1.5 (1.3 to 1.8)
1.5 (1.3 to 1.7)
1.7 (1.5 to 1.9)
1.9 (1.5 to 2.3)
2.2 (0.2 to 6.0)
1.6 (1.5 to 1.7)
1.9 (1.5 to 2.3)
1.6 (1.5 to 1.7)
0.2 0.5 1 2 5
Age group
Favours
control
Favours
alteplase
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Fig 4 | Odds ratios for score 0-1 on modified Rankin scale at
three months adjusted for age and baseline National
Institutes of Health stroke severity scale in patients who
received thrombolytic therapy
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apparent benefit matches that from published rando-
mised trials. These observations extend to older age
groups and only in a small group of patients aged 91-
100 (137patients inalteplase groupand77 in the control
group) did we fail to show significance, with consistent
point estimates butwide confidence intervals. Thepoint
estimates for improved outcomes in this age group are
also consistent with the published data.4849
Weundertookour primary analyses using “shift ana-
lysis,” an analytical approach accepted by the Eur-
opean Drug Licensing agency.37 The Cochran-
Mantel-Haenszel test is a non-parametric approach
that avoids invoking an assumption of a common
odds ratio (that is, proportionality) across all cut points
on the ordinal outcome scale. It provides a conserva-
tive estimate of significance. Because it does not
express the extent of the association, we also applied
an ordinal logistic regression analysis to estimate a
common odds ratio across categories of the modified
Rankin scale. Again, we found significantly better out-
comes, though the proportionality assumption was not
satisfied. Whereas a non-significant result for propor-
tionality would imply that common odds could be
assumed, the converse does not necessarily apply.44
The proportionality assumption test might be oversen-
sitive when applied to large sample sizes.45 Further-
more, it is a global test that cannot differentiate the
heterogeneity resulting from alteplase or other
covariates45 As our sample sizes were large we could
still be justified in using the odds estimated from ordi-
nal logistic regression. Even so, for final confirmation
we used a less powerful dichotomised approach.38 45
With all three methods we reach similar
conclusions.38 50 51
There were improved outcomes among patients
who underwent thrombolysis in age groups from 31
to 90. We found no improved outcomes for patients
aged under 30 and above 90, but the small number of
patients in these groups greatly reduced statistical
power for these analyses and the trends mostly fol-
lowed the same pattern as for intermediate ages.
We chose age and baseline National Institutes of
Health stroke scale score for adjusted analysis mainly
because of their established roles of influence on stroke
outcomes.5253 We also undertook sensitivity analysis,
adjusting for differences in age, sex, history of diabetes
or previous stroke, previous use of an antithrombotic,
baselineNational Institutes ofHealth stroke scale score,
and hypertension, between those who did and did not
undergo thrombolysis.34The adjusted analyses for these
variables confirmed significant findings for improved
outcomes with thrombolysis regardless of age.
The baseline demographic characteristics for the
complete dataset favoured the thrombolysis group.
This influence, however did not extend to patients
aged >80. As a result, though our estimates of overall
effect of alteplase could be biased, the relative differ-
ences between subgroups should remain reliable. We
did notmatch patients by comorbidity score or baseline
functional status, which could be considered a limita-
tion. Premorbid functional status, however, is difficult
to establish reliably in patients with stroke, and the
strong influence of baseline severity on outcome, for
which we did adjust, is known.54 A corresponding ana-
lysis examining the influence of baseline severity on
outcomes in SITS and VISTA data is under way.55
Our conclusions derive merit from being based on a
huge population of patients whowere treated in routine
clinical practice (n=28136) and compared against con-
trols from rigorously conducted neuroprotection trials:
any bias in quality of care should favour the control
group. The limitation of SITS-ISTR data has been dis-
cussed extensively in previous publications.5272856 In
short, SITS-ISTR is a registry, and it is therefore impos-
sible to guarantee completeness of inclusions and to
exclude selection bias.27 For a sample of patients
included in SITS-MOST (monitoring study) (n=6483),
source data were verified onsite by monitors under the
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71-80
81-90
91-100
≤80
>80
All age groups
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0.72 (0.45 to 1.2)
0.84 (0.64 to 1.1)
0.88 (0.74 to 1.1)
0.87 (0.77 to 0.98)
0.86 (0.73 to 1.0)
1.1 (0.59 to 1.9)
0.87 (0.79 to 0.95)
0.89 (0.76 to 1.0)
0.85 (0.78 to 0.92)
0.2 0.5 1 2 5
Age group
Mortality
decreases
Mortality
increases
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Fig 6 | Odds ratios for mortality at three months adjusted for
age and baseline National Institutes of Health stroke severity
scale in patients who received thrombolytic therapy
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Fig 5 | Odds ratios for score 0-2 on modified Rankin scale at
three months adjusted for age and baseline National
Institutes of Health stroke severity scale in patients who
received thrombolytic therapy
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supervision of the relevant national coordinator.27 The
monitors could examine admissions department
records, etc, to check for completeness of data.27 Inves-
tigators agreed to register their patients soon after
admission, before outcome was known.27 Individual
investigators’ results are not published, limiting the
incentive for selection; in contrast, the sharing of total
enrolment numbers might act as an incentive to be
inclusive.27 The almost identical main outcomes in
SITS-MOST27 and randomised controlled trials56 after
adjustment for baseline differences suggests that the
influence from such potential bias is limited. Subse-
quent studies based on SITS-ISTR data also show the
similar outcome for the overall study population com-
pared with the SITS-MOST.5 Selective reporting of
good outcomes in SITS could generate an opposite
bias butwas limited through sitemonitoring procedures
used in the SITS-MOST study.25 None of the neuropro-
tective agents used for the patients in theVISTAcontrol
group has an influence on outcome, and over half of the
VISTA cohort received only placebo.
Because VISTA lacks data on repeat brain imaging
among patients who did not receive thrombolysis, we
had no data on symptomatic intracerebral haemor-
rhage in our control group. Therefore, we compared
the rates between patients aged >80 and ≤80 only with
SITS data. There was no difference in rates between
those aged >80 and ≤80 with the SITS-MOST defini-
tion but slightly higherwith theNINDSdefinition. In a
complementary per protocol analysis of SITS-ISTR
data (that is, patients’ selection based on SITS-MOST
criteria27 except for its age criterion), there was no sig-
nificant difference in rates of symptomatic intra-
cerebral haemorrhage among patients aged >80
compared with the younger cohort (1.8% v 1.7%,
P=0.70, adjusted odds ratio 0.90, 0.73 to 1.09).57 Our
SITS patients in the SITS-VISTA dataset are unse-
lected and therefore rates of symptomatic intracerebral
haemorrhage are slightly higher in the current study.
Regardless, we have shown that even if there were any
more haemorrhages among elderly patients who
receive thrombolysis, based on a conservative defini-
tion, there seems to be no adverse influence on the dis-
tribution of outcomes. In fact, we observe a beneficial
effect onmortality. Others have concluded that factors
such as comorbidity, rather than use of alteplase, are
responsible for the observed increase in late case fatal-
ity among older patients.21 58
Comparison with other studies
We reached the same conclusions as analyses that used
VISTA data or the limited pooled randomised trial
data in elderly patients.59 Elderly patients treated with
thrombolysis in trials reported by VISTA (n=5817)
had significantly better adjusted outcomes than
patients who did not receive thrombolysis (odds ratio
1.3, 1.1 to 1.7; P=0.002).59 Elderly patients treated in
the pooled randomised trials showed a trend towards
better adjusted outcomes (score on modified Rankin
scale 0-2 v 3-6) than those who did nor receive throm-
bolysis (1.8, 0.73 to 4.3; n=137).59 Previous studies
have shown findings consistent with our results but
on small datasets.20 58 60-64
Despite these points, treatment allocation in our
study was not randomised. More extensive data from
randomised controlled trials could more conclusively
answer this question. Two trials are currently examin-
ing this topic.65 66 A trial in Italy has so far enrolled
around 17% of the planned 600 patients over a two
year period.65 In the UK, the International Stroke
Trial-3 (IST-3) is examining outcomes among all
patients who receive thrombolysis and has no upper
age limit in its inclusion criteria.66 Over 12 years, the
trial has enrolled around 2400 patients of the originally
planned 6000. About a third of these patients are aged
>80 and are being treated within the time window of
interest.66 67
Conclusions and policy implication
In our analysis, patients who were treated with intra-
venous alteplase had better outcomes than untreated
patients, and this effect was not dependent on age. In
particular, patients aged over 80 derived similar bene-
fit from treatment as younger patients. The weight of
evidence to date indicates a potential for benefit in the
older people, and there is no a priori reason to suspect a
diminished effect compared with younger people.
Furthermore there are reassuring safety data on the
risk of intracerebral haemorrhage. We conclude that
clinical treatment guidelines should be revised to
remove the age restriction in use of intravenous alte-
plase for acute ischaemic stroke. Age alone should not
be a barrier to treatment.
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